VCYT vs. IBRX
VCYT (Veracyte, Inc.) and IBRX (ImmunityBio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, VCYT returned 26.69%/yr vs 1.91%/yr for IBRX. At a 0.36 correlation, their price movements are largely independent.
Performance
VCYT vs. IBRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VCYT achieves a 27.77% return, which is significantly lower than IBRX's 269.70% return. Over the past 10 years, VCYT has outperformed IBRX with an annualized return of 26.69%, while IBRX has yielded a comparatively lower 1.91% annualized return.
VCYT
- 1D
- 1.13%
- 1M
- 19.45%
- YTD
- 27.77%
- 6M
- 25.33%
- 1Y
- 101.39%
- 3Y*
- 28.20%
- 5Y*
- 5.79%
- 10Y*
- 26.69%
IBRX
- 1D
- 1.39%
- 1M
- 1.39%
- YTD
- 269.70%
- 6M
- 248.57%
- 1Y
- 165.22%
- 3Y*
- 39.61%
- 5Y*
- -12.80%
- 10Y*
- 1.91%
VCYT vs. IBRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VCYT Veracyte, Inc. | 27.77% | 6.31% | 43.95% | 15.93% | -42.40% | -15.82% | 75.29% | 121.94% | 92.65% | -15.63% |
IBRX ImmunityBio, Inc. | 269.70% | -22.66% | -49.00% | -0.99% | -16.61% | -54.39% | 251.72% | 226.72% | -74.16% | -21.50% |
Correlation
The correlation between VCYT and IBRX is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.44 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jul 28, 2015 | 0.36 |
The correlation between VCYT and IBRX shifts across timeframes, from 0.22 (1 year) to 0.44 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
VCYT:
$4.37B
IBRX:
$7.52B
VCYT:
$1.09
IBRX:
-$0.89
VCYT:
8.00
IBRX:
49.99
VCYT:
$541.74M
IBRX:
$140.98M
VCYT:
$386.89M
IBRX:
$132.23M
VCYT:
$99.47M
IBRX:
-$196.14M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VCYT vs. IBRX — Risk / Return Rank
VCYT
IBRX
VCYT vs. IBRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and ImmunityBio, Inc. (IBRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VCYT | IBRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.09 | ||
| Sortino ratioReturn per unit of downside risk | +0.22 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.33 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 2.60 | 3.93 | -1.33 |
| Martin ratioReturn relative to average drawdown | 5.67 | 6.68 | -1.01 |
Loading charts...
Drawdowns
VCYT vs. IBRX - Drawdown Comparison
The maximum VCYT drawdown since its inception was -81.19%, smaller than the maximum IBRX drawdown of -97.30%. Use the drawdown chart below to compare losses from any high point for VCYT and IBRX.
Loading charts...
Drawdown Indicators
| VCYT | IBRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.19% | -97.30% | +16.11% |
Max Drawdown (1Y)Largest decline over 1 year | -39.23% | -42.34% | +3.11% |
Max Drawdown (3Y)Largest decline over 3 years | -50.09% | -79.34% | +29.25% |
Max Drawdown (5Y)Largest decline over 5 years | -71.54% | -91.75% | +20.21% |
Max Drawdown (10Y)Largest decline over 10 years | -81.19% | -97.03% | +15.84% |
Current DrawdownCurrent decline from peak | -33.90% | -82.67% | +48.77% |
Average DrawdownAverage peak-to-trough decline | -48.30% | -84.38% | +36.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.95% | 24.84% | -6.89% |
Volatility
VCYT vs. IBRX - Volatility Comparison
The current volatility for Veracyte, Inc. (VCYT) is 13.48%, while ImmunityBio, Inc. (IBRX) has a volatility of 18.08%. This indicates that VCYT experiences smaller price fluctuations and is considered to be less risky than IBRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VCYT | IBRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.48% | 18.08% | -4.60% |
Volatility (6M)Calculated over the trailing 6-month period | 39.53% | 88.51% | -48.98% |
Volatility (1Y)Calculated over the trailing 1-year period | 60.32% | 104.28% | -43.96% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.42% | 113.43% | -49.01% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 62.01% | 111.38% | -49.37% |
Dividends
VCYT vs. IBRX - Dividend Comparison
Neither VCYT nor IBRX has paid dividends to shareholders.
Financials
VCYT vs. IBRX - Financials Comparison
This section allows you to compare key financial metrics between Veracyte, Inc. and ImmunityBio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
VCYT and IBRX have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IBRX has higher volatility (18.08%) compared to VCYT (13.48%). In terms of maximum drawdown, VCYT dropped -81.19% vs IBRX's -97.30%.
VCYT currently has the higher Sharpe Ratio (1.69 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VCYT and IBRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer